Filing Details

Accession Number:
0000885590-15-000078
Form Type:
4
Zero Holdings:
No
Publication Time:
2015-11-09 17:24:14
Reporting Period:
2015-11-05
Filing Date:
2015-11-09
Accepted Time:
2015-11-09 17:24:14
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
885590 Valeant Pharmaceuticals International Inc. VRX Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1426004 Michael J. Pearson 2150 St. Elzear Blvd. West
Laval A8 H7L 4A8
Chief Executive Officer Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock, No Par Value Disposition 2015-11-05 147,054 $74.67 2,665,009 No 4 S Direct
Common Stock, No Par Value Disposition 2015-11-05 800,345 $76.66 1,864,664 No 4 S Direct
Common Stock, No Par Value Disposition 2015-11-05 350,000 $84.26 1,514,664 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 S Direct
No 4 S Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock, No Par Value 175,000 Indirect In Trust by Spouse
Footnotes
  1. These shares were held by Goldman Sachs as collateral to secure Mr. Pearson's obligations under personal loans Mr. Pearson obtained from Goldman Sachs, to, among other things, finance charitable contributions, including a contribution to Duke University, helping to fund a community swimming pool, purchase shares of the issuer, and meet certain tax obligations related to the vesting and payment of compensatory equity awards. On November 5, 2015, Goldman Sachs ordered the sale of these shares in repayment of the loans. After repayment of the loans with the proceeds from the sale by Goldman Sachs, the loan agreements will terminate and there will be no amounts outstanding under those agreements.
  2. The price reported reflects the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $74.64 to $74.95. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price.
  3. The price reported reflects the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $76.34 to $77.25. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price.